Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > One Last Comment

<< Previous

Bullboard Posts

Next >>

Post by blinkieon Jan 11, 2021 10:57pm

209 Views

Post# 32273444

One Last Comment

The timing of ICO's Presss Releases are quite unorthodox. One on a very slow trading day just before New Years.

Now this news much later into a Monday night vs a pre market announcement in the AM.

In both cases one might miss them if you were not following the stock closely.

I am nit saying these situations are relevant or strategic.

I just find it interesting.

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland